Sukumar Nagendran - 12 Jan 2026 Form 4 Insider Report for Taysha Gene Therapies, Inc. (TSHA)

Reporting relationship: President and Head of R&D, Director
Issuer ticker: TSHA
Reported as of: 12 Jan 2026
Net transaction value: -$712,560
SEC form: 4
Accepted by SEC: 14 Jan 2026, 16:45:07 UTC
Prior SEC filing: 01 Dec 2025
Next SEC filing: 27 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ Kamran Alam, Attorney-in-Fact

Key filing fact

Sukumar Nagendran filed Form 4 for Taysha Gene Therapies, Inc. (TSHA) on 14 Jan 2026.

Key facts

This page summarizes Sukumar Nagendran's Form 4 filing for Taysha Gene Therapies, Inc. (TSHA).
7 reported transactions and 3 derivative rows are listed below.
Accepted by SEC: 14 Jan 2026, 16:45.

Change

Previous filing in this sequence was filed on 01 Dec 2025.
Current net transaction value: -$712,560.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001665124 Primary reporting owner

Nagendran Sukumar

Relationship: President and Head of R&D, Director
Address: C/O TAYSHA GENE THERAPIES, INC., 3000 PEGASUS PARK DRIVE, SUITE 1430, DALLAS
Signature: /s/ Kamran Alam, Attorney-in-Fact
Signature date: 14 Jan 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TSHA transaction

Common Stock

Options Exercise

Transaction value: $77,804
Shares: +111,324
Change %: +11%
Price: $0.6989
Shares after: 1,117,763
Date: 12 Jan 2026
Ownership: Direct

TSHA transaction

Common Stock

Options Exercise

Transaction value: $151,636
Shares: +88,676
Change %: +7.9%
Price: $1.71
Shares after: 1,206,439
Date: 12 Jan 2026
Ownership: Direct

TSHA transaction

Common Stock

Sale

Transaction value: $942,000
Shares: -200,000
Change %: -17%
Price: $4.71
Shares after: 1,006,439
Date: 12 Jan 2026
Ownership: Direct
Footnotes: F1, F2

TSHA transaction

Common Stock

Award

Transaction value: $0
Shares: +427,000
Change %: +42%
Price: $0.000000
Shares after: 1,433,439
Date: 12 Jan 2026
Ownership: Direct
Footnotes: F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TSHA transaction Derivative

Employee Stock Option (right to buy)

Options Exercise

Transaction value: $0
Shares: -111,324
Change %: -50%
Price: $0.000000
Shares after: 111,359
Date: 12 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 111,324
Exercise price: $0.6989
Footnotes: F4

TSHA transaction Derivative

Employee Stock Option (right to buy)

Options Exercise

Transaction value: $0
Shares: -88,676
Change %: -16%
Price: $0.000000
Shares after: 474,941
Date: 12 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 88,676
Exercise price: $1.71
Footnotes: F5

TSHA transaction Derivative

Employee Stock Option (right to buy)

Award

Transaction value: $0
Shares: +274,000
Change %
Price: $0.000000
Shares after: 274,000
Date: 12 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 274,000
Exercise price: $4.86
Footnotes: F6

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 6 footnotes

Footnote F1

This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 11, 2025.

Footnote F2

The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.565 to $4.92 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Footnote F3

Represents a restricted stock unit ("RSU") award. The RSUs will vest in four equal annual installments beginning on January 12, 2027, subject to the Reporting Person's continuous service through each applicable vesting date.

Footnote F4

The shares underlying the option vested or shall vest and become exercisable in three equal annual installments commencing on December 31, 2024, subject to the Reporting Person's continuous service through each applicable vesting date.

Footnote F5

25% of the total number of shares underlying the option vested and became exercisable on January 2, 2025 and the remainder vested or shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.

Footnote F6

25% of the total number of shares underlying the option shall vest and become exercisable on January 12, 2027 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.